QT-019C

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameQT-019C
Drug Alias NameQT-019C
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Qihan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Huanhu HospitalHangzhou Qihan Biotechnology Co LtdShanghai Xiniao Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A